The prognosis for CSR is generally excellent. While immediate vision loss may be as poor as 20/200 in the affected eye, clinically, over 90% of patients regain 20/25 vision or better within 45 days. Once the fluid has resolved, either spontaneously or through treatment, distortion is reduced and visual acuity improves as the eye heals. However, some visual abnormalities can remain even where visual acuity is measured at 20/20. This includes localized reductions in light sensitivity as assessed by visual field testing (microperimetry). Lasting problems include decreased night vision, reduced color discrimination, and localized distortion caused by scarring of the sub-retinal layers. Complications include subretinal neovascularization and pigment epithelial detachment. The disease can re-occur causing progressive vision loss. There is also a chronic form, titled as type II<unk><unk>  retinopathy, which occurs in approximately 5% of cases. This exhibits diffuse rather than localized abnormality of the pigment epithelium, producing a persistent subretinal fluid. The<unk>  fluid in these cases tends to be shallow rather than dome shaped. The prognosis for this condition is less favorable and continued clinical consultation is advised.
Central serous chorioretinopathy
Vitreoretinopathy
Ocular ischemic syndrome
Optic neuritis
Ischemic optic neuropathy
Posterior ischemic optic neuropathy
Anterior ischemic optic neuropathy
Toxoplasmic chorioretinitis